As per MRFR analysis, the Heart Valves Market Size was estimated at 9.09 (USD Billion) in 2024. The Heart Valves Market Industry is expected to grow from 10.2 (USD Billion) in 2025 to 28.74 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 12.20% during the forecast period (2025 - 2034).
An increase in the burden of valvular heart disease, an increase in the number of elderly people, and a move toward sedentary behavior, are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The main drivers of the cardiac valve market growth are the rising number of heart replacement and repair surgeries, particularly minimally invasive procedures. The prevalence of aortic stenosis, heart valve vegetation, and other valvular stenosis illnesses is rising, which is increasing the number of operations carried out globally. The German Heart Surgery Report estimates that 34,394 heart valve operations were completed in Germany last year. During the projected period, this is anticipated to fuel the expansion of the global market. Additionally, the market is expected to grow rapidly due to the increasing trend toward minimally invasive surgery, which includes transcatheter heart valve replacement.
The launch of new products on the market is expected to lead to an expansion of the cardiac valve market throughout the anticipated timeframe. The market for artificial heart valves has already undergone a revolution because to the development of tissue valves. With the introduction of solutions that require little to no surgery and no sutures, the industry is anticipated to significantly expand. A transcatheter aortic valve replacement (TAVR) system called Evolut PRO+, for instance, was introduced by Medtronic in the United States in September 2019. In addition to this, numerous manufacturers are doing specialized research and clinical trials for the creation of novel heart valves. As an illustration, Abbott began the TRILUMINATE pivotal study in September 2019 to assess TriClip, a transcatheter tricuspid valve repair used to treat tricuspid regurgitation. In the upcoming years, similar studies by important manufacturers are projected to increase Heart Valves Market revenue.
Increased geriatric population, shift in people's lifestyles from active to sedentary, novel developments in heart valves, increased awareness of surgical treatment options, and rising demand for minimally invasive surgeries are all factors driving the market's expansion. For instance, the American College of Cardiology estimates that every year, heart valve disease affects about 5 million Americans. However, some of the key constraints inhibiting the market's growth include the high cost of prosthetic heart valves and the availability of other solutions for treating heart valve disease. Another significant factor influencing the heart valve repair and replacement market is the ability of computational tools to mimic additional fluid mechanics properties like pressure decreases, regurgitation volumes, or turbulence. Additionally, the availability of computational tools makes it possible to accurately diagnose valvar disease, which results in appropriate treatment and grows the market for prosthetic heart valve repair and replacement. Thus, driving the market revenue of Heart Valves.
The Market segments of Heart Valves, based on product type, includes replacement and repair. Replacement segment dominated the global market in 2022. The number of valve replacement surgeries has significantly increased, and excellent health reimbursement rates are to blame for this. The rise of the replacement segment is predicted to be aided by the rising prevalence of valve illness and technological advancements in cardiac valve replacement procedures.
The Heart Valves Market segmentation, based on valve type, includes tissue valve and mechanical valve. Tissue valve segment dominated the global market in 2022. A significant share of the tissue valves market has been achieved as a result of the introduction of bioprosthetic valves with benefits like flexibility, strength, and a reduced requirement for anticoagulants. Additionally, this reduced the market's demand for mechanical valves. Additionally, thromboembolic problems linked to mechanical valves caused the tissue valve section to expand more quickly.
The Market segmentation of Heart Valves, based on procedure, includes surgical and transcatheter. Transcatheter segment dominated the Heart Valves Market in 2022. Transcatheter heart valve demand is rising as a result of a steady movement toward minimally invasive procedures among patients who are becoming more aware of their options.
The Heart Valves Market segmentation, based on end user, includes hospitals, specialty clinics, and others. Hospitals segment dominated the market of Heart Valves in 2022. The expansion of the hospital segment is primarily caused by an increase in hospital procedures, attractive health reimbursement, and improved government standards for the care of vulvar illnesses. Due to the rise in private practitioners and unmet patient needs, the specialty clinics & others market is predicted to grow.
Figure 1: Heart Valves Market, by End User, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Heart Valves Market dominated this market in 2022 (45.80%). This is due to an increase in medical knowledge, new product introductions, and regulatory rules that make it simple to produce and maintain heart valve devices. In addition, the rising frequency of lifestyle diseases like diabetes and obesity is a significant component in the region's domination. Further, the U.S. market of Heart Valves held the largest market share, and the Canada market of Heart Valves was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: HEART VALVES MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Heart Valves market accounted for the healthy market share in 2022. The high frequency of heart valve problems, product improvements, the volume of heart valve replacement surgeries, and the well-established healthcare infrastructure are the main drivers of the market's growth. Further, the German market of Heart Valves held the largest market share, and the U.K market of Heart Valves was the fastest growing market in the European region
The Asia Pacific Heart Valves market is expected to register significant growth from 2023 to 2032. This is because aortic stenosis and other cardiac illnesses are becoming more common, healthcare infrastructure is increasing in places like China and India, and industry participants are constantly looking for opportunities to invest in new markets. For instance, aortic stenosis is thought to affect 1 in 8 geriatric Australians, according to information provided by Hope for Hearts. Additionally, it was calculated that at least 97,000 Australians over the age of 55 suffer from severe aortic stenosis (AS). Moreover, China’s market of Heart Valves held the largest market share and the Indian market of Heart Valves was the fastest growing market in the Asia-Pacific region.
Heart Valves Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the market of Heart Valves, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Heart Valves industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Heart Valves industry to benefit clients and increase the market sector. In recent years, the Heart Valves industry has offered some of the most significant advantages to medicine. Major players in the Heart Valves market, including Edwards Lifesciences Corporation, Abbott, Medtronic, LivaNova PLC, Boston Scientific Corporation, CryoLife, Inc., and Micro Interventional Devices, Inc., are attempting to increase market demand by investing in research and development Product Types.
An organization that develops, produces, and markets devices for structural heart disease, critical care, and surgical monitoring is called Edwards Lifesciences Corp (Edwards Lifesciences). The company sells transcatheter heart valves, pressure monitoring equipment, hemodynamic monitoring equipment, surgical valve replacement and repair devices, as well as other tools and accessories. The management of clotting, hypotension, and sepsis, as well as transcatheter aortic valve replacement (TAVR), blood conservation, infection control, and improved surgical recovery are just a few therapies that its products are used in. The business sells its goods directly to consumers as well as through a network of independent distributors in regions like North America, Europe, and Asia-Pacific. The American city of Irvine serves as the headquarters of Edwards Lifesciences. The MITRIS RESILIA valve was approved by the US Food and Drug Administration (FDA) in March 2022 for Edwards Lifesciences. It is a tissue valve replacement made especially for the mitral location of the heart.
The mission of JenaValve Technology, a developer and producer of transcatheter aortic valve replacement (TAVR) systems, is to enhance the quality of life for people with structural heart diseases. Because of an anatomically based locator fixation and dual sealing valve design, the company's technology uses porcine pericardial tissue and a self-expanding nitinol frame with a transfemoral delivery system that does not require rapid pacing. This enables patients with ease of use, decreased risks of paravalvular regurgitation, and durability of hemodynamic results. With the Chinese company Peijia Medical Limited, JenaValve Technology, Inc. engaged into a strategic investment and exclusive technology licensing deal in January 2022. To treat patients with either severe symptomatic aortic regurgitation (AR) or severe symptomatic aortic stenosis, Peijia has made and will continue to make a cash and equity investment in JenaValve in exchange for the exclusive rights to develop and market JenaValve's cutting-edge Trilogy TAVR systems in the Greater China region.
Key Companies in the market of Heart Valves include
Heart Valves Industry Developments
DECEMBER 2024 Anteris Technologies' IPO: Anteris Technologies completed its initial public offering (IPO) on the Nasdaq market with the opening 'AVR' ticker symbol, reaching a funding mark of 88.8 million dollars. The institution focuses on TAVR (transcatheter aortic valve replacement) devices.
AUGUST 2024 Johnson & Johnson Merger with V-Wave Ltd.: Johnson & Johnson agreed to buy V-Wave Ltd, a private company working in heart failure\'s therapeutics, for an upfront payment of $600 million, with potential additional payments of up to $1.1 billion, making a total of $1.7 billion. V-Wave heart failure device specifically targets reducing left atrial pressure by shunting between the atria which can improve cardiovascular events and decrease hospital admissions.
SEPTEMBER 2024 Humacyte's Lab-Grown Blood Vessels: Humacyte, a biotech company, is the first to create lab-grown blood vessels, a massive achievement in tissue engineering. The vessels have been used in clinical trials for trauma cases and have shown great success in improving blood flow and preventing amputations.
September 2021 Boston Scientific Expansion: Boston Scientific Corporation has expanded its business portfolio with the development of new interventional cardiology products by acquiring Devoro Medical, Inc., which has proprietary technologies for removing blood clots. Devoro’s WOLF Thrombectomy Platform that is capable of rapid clot targeting and capturing is a great addition to Boston Scientific’s interventional cardiology products.
November 2021 : Abbott's Amulet Occluder FDA Approval: Abbott Laboratories gained the US Food and Drug Administration (FDA) sanction for the use of the Amplatzer Amulet Left Atrial Appendage Occluder. The device provides a percutaneous option for patients suffering from atrial fibrillation who are at high risk of ischemic strokes which eliminate the need for long-term anticoagulation therapy.
December 2021: Medtronic Announcements: Medtronic plc announces the first investigational Intrepid Transcatheter Tricuspid Valve Replacement (TTVR) system implant procedure in a patient with severe tricuspid regurgitation.
| Report Attribute/Metric | Details |
| Market Size 2024 | 9.09 (USD Billion) |
| Market Size 2025 | 10.20 (USD Billion) |
| Market Size 2034 | 28.74 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 12.20 % (2025 - 2034) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2034 |
| Historical Data | 2020 - 2024 |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Type, Valve Type, Procedure, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, German, France, U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Edwards Lifesciences Corporation, Abbott, Medtronic, LivaNova PLC, Boston Scientific Corporation, CryoLife, Inc., and Micro Interventional Devices, Inc. |
| Key Market Opportunities | · Technological advancements |
| Key Market Dynamics | · Rise in burden exerted by valvular heart diseases, increase in geriatric population, and shift towards sedentary lifestyle |
Heart Valves Market Highlights:
Frequently Asked Questions (FAQ) :
The Heart Valves Market size was valued at USD 7.2 Billion in 2022.
The global market is projected to grow at a CAGR of 12.20% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are Edwards Lifesciences Corporation, Abbott, Medtronic, LivaNova PLC, Boston Scientific Corporation, CryoLife, Inc., and Micro Interventional Devices, Inc.
The Replacement Product Type dominated the market in 2022.
The Tissue Valve, Valve Type had the largest share in the global market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
